Statistics from Altmetric.com
Pittsburgh, Pennsylvania, USA.
107 adolescents who were 13–18 years of age (mean age 16 y, 76% girls), met DSM-III-R criteria for MDD, and had a Beck Depression Inventory score ≥13. Exclusion criteria were ongoing physical or sexual abuse; psychosis; or bipolar, obsessive compulsive, eating, or substance abuse disorders. 92% of patients completed ≥7 of 8 assessments, and 97% were included in the analyses.
Patients were allocated to 1 of 3 groups: cognitive behavioural therapy (CBT) (n=37), systemic behavioural family therapy (n=35), or non-directive supportive therapy (n=35). Psychotherapy lasted 12–16 weeks, and patients were followed up for 24 months thereafter.
Main outcome measures
Rates of remission (≥2 weeks and ≤2 months with absence of MDD), recovery (≥2 months with absence of MDD), relapse (an episode of MDD during the period of remission), and recurrence (an episode of MDD during the period of recovery); severity of depression (Kiddie Schedule for Affective Disorders and Schizophrenia and the Beck Depression Inventory); functional status (Children's Global Assessment Scale); cognitive distortion (Children's Negative Cognitive Error Questionnaire and the Beck Hopelessness Scale); family environment (Conflict Behavior Questionnaire, Areas of Change Questionnaire, and Family Assessment Device); and parents' current and lifetime psychiatric disorders (Schedule for Affective Disorders and Schizophrenia—Lifetime version).
The 3 groups did not differ for any of the clinical outcomes at the end of the 2 year follow up. The study had 80% power to detect effect sizes ranging from 0.30–0.50. Remission and recovery rates were 84% and 83%, respectively, for the group as a whole. 30% of recovered patients had 1 recurrence, and 8% had 2 recurrences. 21% of patients continued to have substantial depressive symptoms and poor functioning.
In adolescents with major depressive disorder, most patients improved after 24 months of follow up, regardless of type of psychotherapy (cognitive behavioural therapy, systemic behavioural family therapy, or non-directive supportive therapy). 30% of adolescents had recurrences, however, and 21% had chronic depression.
Birmaher et al's findings of the equivalence of 3 different forms of therapy in adolescents' recovery from depression and recurrence during 2 years of follow up need to be interpreted with caution as to ecological validity. For example, the 12-fold reduction in rate of remission found in the group recruited through advertising raises the question of how different are patients and families who do not respond to advertising but go to clinics for treatment or who seek help in the privacy of traditional, non-institutional, private practice mental health settings. Unfortunately, cautions about the study's ecological validity are likely to be lost in a “keep psychotherapy cheap” climate where some managed healthcare organisations take advantage of the stigma of mental illness and popular prejudices that all therapy is the same. This study should not be used to promote practices such as behavioural carveouts, which limit both resources and choice, or to justify funnelling patients to the cheapest “providers” rather than to the most highly trained clinicians. A subtle but more valid inference from the study's most robust finding is the importance of creating access to mental healthcare systems and practices that promote choice and hope for potential patients.1–3
The finding that CBT is effective in the short term but not the long term must be considered cautiously also. In private practice, achieving such meaningful, yet hard to measure, long term mental health outcomes as autonomy and authenticity are more likely to be clinical priorities.4 This study confirms clinical experience, which suggests that the keys to effective treatment are attention to the therapeutic alliance and open, non-transference distorted communication rather than simply frequent booster sessions. This is, in effect, an informed consent process rather than the pro forma informed consent of most study designs.4
Source of funding: National Institute of Mental Health.
For correspondence: Dr B Birmaher, Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA. Fax +1 412 624 3703.
↵† Information provided by author.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.